See more : Air Canada (ACDVF) Income Statement Analysis – Financial Results
Complete financial analysis of Synaptogenix, Inc. (SNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synaptogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pcgh Zdp Plc (PGHZ.L) Income Statement Analysis – Financial Results
- Allied Properties Real Estate Investment Trust (APYRF) Income Statement Analysis – Financial Results
- Theratechnologies Inc. (TH.TO) Income Statement Analysis – Financial Results
- Sama Resources Inc. (SME.V) Income Statement Analysis – Financial Results
- Ultracab (India) Limited (ULTRACAB.BO) Income Statement Analysis – Financial Results
Synaptogenix, Inc. (SNPX)
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| Gross Profit | -6.35K | -5.71K | -4.97K | -4.87K | -4.39K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.32M | 4.34M | 3.07M | 5.67M | 4.89M |
| General & Administrative | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 6.26M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 28.36K | 0.00 | 0.00 |
| Operating Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Cost & Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Interest Income | 1.65M | 335.04K | 7.11K | 153.21K | 378.71K | 127.11K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| EBITDA | -8.31M | -16.13M | -12.61M | -11.15M | -15.51M | -11.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -26.36M | -12.62M | -9.46M | -15.51M | -11.15M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.28M | 10.56M | 7.11K | -1.55M | 378.71K | 127.11K |
| Income Before Tax | -6.04M | -5.57M | -12.61M | -12.70M | -15.13M | -11.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -115.89K | -7.11K | 1.55M | -378.71K | 1.00 |
| Net Income | -6.04M | -5.46M | -12.60M | -14.25M | -14.76M | -11.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| EPS Diluted | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| Weighted Avg Shares Out | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
| Weighted Avg Shares Out (Dil) | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
Synaptogenix Responds to FDA Approval of Aducanumab
Source: https://incomestatements.info
Category: Stock Reports